Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety,
the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic
cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with
non-small-cell lung cancer.